Body mass index and magnetic resonance markers of brain integrity in adults - PubMed (original) (raw)
Body mass index and magnetic resonance markers of brain integrity in adults
Stefan Gazdzinski et al. Ann Neurol. 2008 May.
Abstract
Objective: Obesity and being overweight during adulthood have been consistently linked to increased risk for development of dementia later in life, especially Alzheimer's disease. They have also been associated with cognitive dysfunction and brain structural alterations in otherwise healthy adults. Although proton magnetic resonance spectroscopy may distinguish between neuronal and glial components of the brain and may point to neurobiological mechanisms underlying brain atrophy and cognitive changes, no spectroscopic studies have yet assessed the relationships between adiposity and brain metabolites.
Methods: We have utilized magnetic resonance imaging and proton magnetic resonance spectroscopic imaging data from 50 healthy middle-aged participants (mean age, 41.7 +/- 8.5 years; 17 women), who were scanned as control subjects for another study.
Results: After adjustment for age and sex, greater body mass indices (BMIs) correlated with: (1) lower concentrations of N-acetylaspartate (spectroscopic marker of neuronal viability) in frontal (p = 0.001), parietal (p = 0.006), and temporal (p = 0.008) white matter; (2) lower N-acetylaspartate in frontal gray matter (p = 0.01); and (3) lower concentrations of choline-containing metabolites (associated with membrane metabolism) in frontal white matter (p = 0.05).
Interpretation: These results suggest that increased BMI at midlife is associated with neuronal and/or myelin abnormalities, primarily in the frontal lobe. Because white matter in the frontal lobes is more prone to the effects of aging than in other lobes, our results may reflect accelerated aging in individuals with high levels of adiposity. Thus, greater BMI may increase the odds of developing an age-related disease, such as Alzheimer's disease.
Figures
Fig
Concentrations of N-acetylaspartate (NAA; marker of neuronal viability, in institutional units [i.u.]) as a function of body mass index (BMI), separately for men (solid circles) and women (open circles). The relationships were not covaried for age, which was a nonsignificant factor in the model. GM = gray matter; WM = white matter.
Similar articles
- Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging.
Meyerhoff DJ, MacKay S, Constans JM, Norman D, Van Dyke C, Fein G, Weiner MW. Meyerhoff DJ, et al. Ann Neurol. 1994 Jul;36(1):40-7. doi: 10.1002/ana.410360110. Ann Neurol. 1994. PMID: 8024260 - Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging.
MacKay S, Meyerhoff DJ, Constans JM, Norman D, Fein G, Weiner MW. MacKay S, et al. Arch Neurol. 1996 Feb;53(2):167-74. doi: 10.1001/archneur.1996.00550020079018. Arch Neurol. 1996. PMID: 8639067 Free PMC article. - Physiological neuronal decline in healthy aging human brain - An in vivo study with MRI and short echo-time whole-brain (1)H MR spectroscopic imaging.
Ding XQ, Maudsley AA, Sabati M, Sheriff S, Schmitz B, Schütze M, Bronzlik P, Kahl KG, Lanfermann H. Ding XQ, et al. Neuroimage. 2016 Aug 15;137:45-51. doi: 10.1016/j.neuroimage.2016.05.014. Epub 2016 May 7. Neuroimage. 2016. PMID: 27164326 Free PMC article. - 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.
Jones RS, Waldman AD. Jones RS, et al. Neurol Res. 2004 Jul;26(5):488-95. doi: 10.1179/016164104225017640. Neurol Res. 2004. PMID: 15265265 Review.
Cited by
- Nutrition and neurodegeneration: epidemiological evidence and challenges for future research.
Gillette-Guyonnet S, Secher M, Vellas B. Gillette-Guyonnet S, et al. Br J Clin Pharmacol. 2013 Mar;75(3):738-55. doi: 10.1111/bcp.12058. Br J Clin Pharmacol. 2013. PMID: 23384081 Free PMC article. Review. - A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly.
Ho AJ, Stein JL, Hua X, Lee S, Hibar DP, Leow AD, Dinov ID, Toga AW, Saykin AJ, Shen L, Foroud T, Pankratz N, Huentelman MJ, Craig DW, Gerber JD, Allen AN, Corneveaux JJ, Stephan DA, DeCarli CS, DeChairo BM, Potkin SG, Jack CR Jr, Weiner MW, Raji CA, Lopez OL, Becker JT, Carmichael OT, Thompson PM; Alzheimer's Disease Neuroimaging Initiative. Ho AJ, et al. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8404-9. doi: 10.1073/pnas.0910878107. Epub 2010 Apr 19. Proc Natl Acad Sci U S A. 2010. PMID: 20404173 Free PMC article. - Metabolic syndrome as a risk factor for neurological disorders.
Farooqui AA, Farooqui T, Panza F, Frisardi V. Farooqui AA, et al. Cell Mol Life Sci. 2012 Mar;69(5):741-62. doi: 10.1007/s00018-011-0840-1. Epub 2011 Oct 15. Cell Mol Life Sci. 2012. PMID: 21997383 Free PMC article. Review. - Relation of regional gray and white matter volumes to current BMI and future increases in BMI: a prospective MRI study.
Yokum S, Ng J, Stice E. Yokum S, et al. Int J Obes (Lond). 2012 May;36(5):656-64. doi: 10.1038/ijo.2011.175. Epub 2011 Sep 6. Int J Obes (Lond). 2012. PMID: 21894161 Free PMC article. - Accelerated recovery from acute hypoxia in obese mice is due to obesity-associated up-regulation of interleukin-1 receptor antagonist.
Sherry CL, Kim SS, Freund GG. Sherry CL, et al. Endocrinology. 2009 Jun;150(6):2660-7. doi: 10.1210/en.2008-1622. Epub 2009 Feb 12. Endocrinology. 2009. PMID: 19213834 Free PMC article.
References
- Meyer JS, Rauch GM, Crawford K, et al. Risk factors accelerating cerebral degenerative changes, cognitive decline and dementia. Int J Geriatr Psychiatry. 1999;14:1050–1061. - PubMed
- Gustafson D. Adiposity indices and dementia. Lancet Neurol. 2006;5:713–720. - PubMed
- Jagust W. What can imaging reveal about obesity and the brain? Curr Alzheimer Res. 2007;4:135–139. - PubMed
- Gustafson D, Lissner L, Bengtsson C, et al. A 24-year follow-up of body mass index and cerebral atrophy. Neurology. 2004;63:1876–1881. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AA010788-12/AA/NIAAA NIH HHS/United States
- P01 AA11493/AA/NIAAA NIH HHS/United States
- P01 AA011493/AA/NIAAA NIH HHS/United States
- P01 AA011493-05/AA/NIAAA NIH HHS/United States
- R01 AA010788/AA/NIAAA NIH HHS/United States
- R01 AA10788/AA/NIAAA NIH HHS/United States
- P01 AA011493-04/AA/NIAAA NIH HHS/United States
- R01 AA010788-11/AA/NIAAA NIH HHS/United States
- P01 AA011493-03/AA/NIAAA NIH HHS/United States
- R01 AA010788-13/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical